Resistance of Targeted Therapies Excluding Antibodies for Lymphomas

  • Andrés J. M. Ferreri

Part of the Resistance to Targeted Anti-Cancer Therapeutics book series (RTACT, volume 17)

Table of contents

  1. Front Matter
    Pages i-xiii
  2. Mattias Mattsson, Lydia Scarfò
    Pages 1-22
  3. Mary Ann Anderson, Andrew W. Roberts, John F. Seymour
    Pages 23-43
  4. Kevin Barley, Samir Parekh
    Pages 45-71
  5. Teresa Calimeri, Andrés J. M. Ferreri
    Pages 85-105
  6. Back Matter
    Pages 135-138

About this book


In the last decade, the literature on molecular mechanisms and activated pathways in the different lymphoma categories increased exponentially, which was followed by a more diffuse and successful use of targeted therapies. In this book, expert authors revisit the most relevant aspects of these therapies, with special emphasis on molecular mechanisms and clinical effects of resistance. The knowledge of the underlying mechanisms involved in tumor resistance to target therapies is of paramount importance because they will result in a better selection of patients with sensitive disease and the establishment of suitable combinations of drugs that target different molecules and could overcome the established resistance. 


Lymphomas Malignancies Investigative trials Resistance Relapse

Editors and affiliations

  • Andrés J. M. Ferreri
    • 1
  1. 1.Department of Onco-HematologyUnit of Lymphoid Malignancies, IRCCS San Raffaele Scientific InstituteMilanItaly

Bibliographic information

  • DOI
  • Copyright Information Springer International Publishing AG, part of Springer Nature 2018
  • Publisher Name Springer, Cham
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-3-319-75183-2
  • Online ISBN 978-3-319-75184-9
  • Series Print ISSN 2196-5501
  • Series Online ISSN 2196-551X
  • Buy this book on publisher's site